Figure 2.

AMPKα1 protein and activity are decreased in PMVECs by shRNA. A) Immunoblot of control (wt, wild-type) PMVECs and PMVECs engineered to express shRNA constructs (lanes 1–6) targeted to 6 different regions of AMPKα1 mRNA. β-actin, loading control. B) Basal AMPKα activity (Con) is sensitive to stimulation by AICAR (+) and inhibition by compound C (−). Cells expressing shRNA to AMPKα1 (Δα1) have reduced AMPKα1 activity (n=3). *P < 0.05. C) Treatments that alter AMPK activity do not decrease ATP content (n=3). Values are means ± se.